Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings
IKT·Reported May 15, 2024·Before market open
Diluted EPS came in at $-0.73, beat the $-0.79 consensus by $0.06.
Diluted EPS
$-0.73beat by $0.06
Consensus: $-0.79
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Inhibikase Therapeutics, Inc.'s Q1 2024 earnings report.
Inhibikase Therapeutics, Inc. (IKT) reported Q1 2024 earnings on May 15, 2024 before market open.
Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.73 for Q1 2024.
EPS beat the consensus estimate of $-0.79 by $0.06.
You can read the 10-Q periodic report (0000950170-24-060579) directly on SEC EDGAR. The filing index links above go to sec.gov.